...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Azacitidine in the Front-line Treatment of Therapy-related Myeloid Neoplasms: A Multicenter Case Series
【24h】

Azacitidine in the Front-line Treatment of Therapy-related Myeloid Neoplasms: A Multicenter Case Series

机译：阿扎胞苷在与治疗有关的髓样肿瘤的一线治疗中：一个多中心案例系列。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: A continued increase in the incidence of therapy-related myeloid neoplasnis (t-MN) is expected due to the improvement of chemotherapeutic treatments for solid and haematological malignancies. The use of 5-azacytidine (AZA) is emerging in these patients. We, therefore, analyzed the outcome of patients with t-MN ineligible for intensive chemotherapy treated in the front-line with AZA. Patients and Methods: We retrospectively collected clinical data from consecutive patients with t-MN treated in the front-line with AZA at five Haematology Centers. Response to therapy, overall survival (OS) and safety were considered. Results: The overall response rate was of 35.7% with a median OS of 9.6 months. Patients who were heavily pre-treated for their primary malignancy (more than 3 lines of chemotherapy) presented a significant inferior OS (4.9 months). The principal reported toxicity was haematological with severe infections occurring in a minority of patients. Fatigue was the most common extra-haematological toxicity. Conclusion: New aspects emerged on the management of t-MN. AZA may represent a reasonable choice for patients ineligible for intensive treatment, with the exception of heavily pre-treated patients who presented -anyway- a worse outcome.
机译：背景/目的：由于对实体和血液恶性肿瘤的化学治疗方法的改进，预计与治疗有关的髓样瘤形成（t-MN）的发生率将继续增加。这些患者中出现了5-氮杂胞苷（AZA）的使用。因此，我们分析了不适合进行AZA一线治疗的强化化疗的t-MN患者的预后。患者和方法：我们回顾性收集了五个血液学中心在AZA一线治疗的连续t-MN患者的临床资料。考虑对治疗的反应，总生存期（OS）和安全性。结果：总缓解率为35.7％，中位OS​​为9.6个月。对其原发恶性肿瘤进行大量预处理的患者（超过3个化疗方案），其OS明显较差（4.9个月）。报告的主要毒性是血液学，少数患者发生严重感染。疲劳是最常见的血液外毒性。结论：t-MN的管理出现了新的方面。对于没有资格接受强化治疗的患者，AZA可能是一个合理的选择，但经过严重治疗的患者无论如何都会出现较差的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号